Zoetis Inc. research snapshot
ZTS AI stock analysis currently reads Zoetis Inc. as a global animal health leader with strong brands, high margins, and durable veterinary channels, but the stock is still working through a sharp reset after weaker companion animal demand, competitive pressure, and reduced 2026 guidance. At the July 9, 2026 data cutoff, ZTS traded near $75.35 with a verified market value near $31.59 billion. The company reported first-quarter 2026 revenue of $2.262 billion, net income of $601 million, adjusted diluted EPS of $1.53, and updated full-year 2026 revenue guidance of $9.680 billion to $9.960 billion. This ZTS AI stock analysis is informational only and is not investment advice.
Current price
$75.35
Market cap
$31.59 billion verified market value, with third-party references near $31.56 billion to $31.84 billion
AI score
58 / 100
Rating
High-quality animal health franchise under a reset valuation after weaker companion animal momentum and reduced 2026 guidance
Trend status
Bearish to stabilizing, with price below longer moving averages, RSI near neutral, and support clustered near the low $70s
Data cutoff (updated weekly)
July 9, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Zoetis sells medicines, vaccines, diagnostics, genetic tests, biodevices, and precision animal health products across companion animal and livestock markets in more than 100 countries. | High |
| Moat | The moat comes from trusted veterinary brands, regulatory approvals, customer relationships, global scale, R&D, manufacturing, distribution, and species-specific know-how. | Medium-high |
| Management | CEO Kristin Peck has led Zoetis through portfolio expansion and shareholder returns, but the current test is restoring confidence after weaker growth and a 2026 guidance reset. | Medium-high |
| Financial trend | Fiscal 2025 revenue rose 2% to $9.467 billion and net income rose 8% to $2.673 billion, while Q1 2026 revenue grew 3% but organic operational revenue was flat. | High |
| Valuation | At $75.35, ZTS screens near 12.35x EPS, 9.61x book value, 14.03x free cash flow per share, 3.38x sales per share, and a 2.81% dividend yield. | High |
| Technical trend | The chart remains below longer moving-average references, with Investing.com showing daily Strong Sell and AltIndex showing support near $71.86. | Medium |
| Risk level | Key risks include companion animal spending, generic competition, pain product safety concerns, livestock cycles, foreign exchange, R&D productivity, leverage, and multiple compression. | Medium-high |
| AI confidence | Descriptive confidence is high because source data is rich. Forecast confidence is lower because the stock has already had a large repricing and sentiment can change after each earnings update. | High data confidence |
| Investment certainty | ZTS has a stronger business than its recent chart suggests, but a margin of safety depends on evidence that 2026 guidance is achievable and product competition is contained. | Medium |
ZTS AI stock forecast
The ZTS AI stock forecast uses scenario math around the $75.35 quote reference and Zoetis updated 2026 adjusted EPS guidance midpoint of $6.925. The audited three-year model produced a bearish area near $53.40, a base area near $98.40, and a bullish area near $152.70 before dividends.
$140 to $160
More likely if 2026 revenue lands near the upper half of the $9.680 billion to $9.960 billion guide, companion animal organic growth improves, dermatology and parasiticide franchises hold share, livestock remains resilient, and the market restores a high-teens earnings multiple.
$90 to $105
More likely if adjusted EPS compounds at a low-single-digit pace from the $6.925 guidance midpoint, pricing and cost control offset softer pet-owner spending, and investors value ZTS near 13x forward scenario earnings.
$50 to $58
More likely if organic sales growth misses the 2% to 5% guide, generic and branded competition pressure key companion animal products, litigation or safety concerns rise, or the market values ZTS closer to 9x lower earnings.
ZTS AI technical analysis
ZTS AI technical analysis is still cautious as of the July 9, 2026 cutoff. Investing.com showed daily Strong Sell at the July 8 close, RSI near 50.62, 50-day simple moving average near $74.40, and 200-day simple moving average near $77.73. AltIndex showed a wider six-month support level near $71.86 and resistance near $128.57, with price below its long moving averages.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $75.35 | July 9, 2026 quote reference used for market-cap and valuation verification. |
| Immediate support | $71.86 to $74.83 | AltIndex listed six-month support near $71.86 and Investing.com classic S1 near $74.83 after the July 8 close. |
| Deeper support | $53 to $58 | Bearish scenario valuation area if revenue growth and product competition worsen from current assumptions. |
| Near resistance | $75.57 to $77.73 | Investing.com classic R1 was $75.57 and the 200-day simple moving average was $77.73. |
| Higher resistance | $98 to $129 | Base scenario area near $98 and AltIndex six-month resistance near $128.57 define the next larger test if sentiment improves. |
| Moving averages | MA50 about $74.40 to $78.00, MA200 about $77.73 to $107.90 | Investing.com and AltIndex feeds disagree on longer moving averages, so treat the trend as a zone rather than a precise line. |
| Momentum | RSI about 43.5 to 50.62 | Momentum is neutral by RSI, but daily aggregate signals remain weak because longer moving averages are still overhead. |
| Volume | About 4.7 million shares on July 7 versus 7.8 million 50-day average | MarketWatch reported below-average volume during a four-day rally, so follow-through volume matters. |
| Volatility | Large drawdown from $161.77 52-week high | The stock remains more than 50% below its prior 52-week high, so headline sensitivity is still elevated. |
| Invalidation | Sustained close below $71 | A durable break below recent support would weaken the stabilization case and shift attention toward bearish scenario math. |
ZTS AI trading strategy
The ZTS AI trading strategy below is a rules-based research framework, not personalized advice. It connects price action to 2026 guidance, companion animal demand, competitive pressure, litigation updates, R&D pipeline evidence, cash generation, leverage, and dividend coverage.
Look for ZTS to hold above the low-$70s support area, reclaim the $77 to $80 moving-average zone, and pair the move with evidence that organic revenue growth is moving back toward management guidance.
A failed reclaim or sustained close below $71 should reduce setup confidence, especially if another earnings update points to weaker companion animal demand or more price pressure.
If ZTS revisits the $71 to $75 range while 2026 EPS guidance remains intact, compare the entry price with updated free cash flow, net debt, product competition, litigation disclosures, and veterinary channel commentary.
Do not treat the drawdown as automatically cheap if the decline is tied to lower organic growth, product-safety concerns, or a second guidance cut.
Track companion animal revenue, livestock resilience, dermatology, parasiticides, pain and sedation products, diagnostics, R&D expense, gross margin, adjusted EPS, cash, debt, repurchases, and dividend declarations.
Position sizing should reflect that ZTS is a high-quality healthcare supplier facing a growth reset, not a risk-free consumer staple.
Investment research summary
Customers pay Zoetis because veterinarians, livestock producers, and pet owners need reliable medicines, vaccines, diagnostics, and animal care tools that improve animal health and productivity.
The moat is built from trusted brands, regulatory approvals, product breadth, veterinary relationships, R&D capability, global manufacturing, distribution, and data across companion animal and livestock species.
The thesis fails if pet-owner spending remains weak, generics pressure key franchises, pain product safety concerns widen, new launches disappoint, livestock demand softens, leverage limits capital returns, or premium valuation does not return.
Kristin Peck has led Zoetis as a focused animal health company with continued R&D investment and shareholder returns. The current capital-allocation test is balancing buybacks, dividends, pipeline investment, and debt after a growth reset.
Animal health has long-term support from pet humanization, aging pets, protein demand, veterinary standards, diagnostics, and biologic innovation, but near-term demand can still be pressured by consumer budgets and producer economics.
The lower stock price has compressed valuation to about 12.35x EPS and 14.03x free cash flow per share, but the margin of safety depends on whether the updated 2026 guidance is a floor or another step in a longer reset.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Q1 2026 revenue | $2.262 billion, up 3% reported and flat organic operational | Zoetis Q1 2026 results release | July 9, 2026 |
| Q1 2026 adjusted diluted EPS | $1.53 | Zoetis Q1 2026 results release | July 9, 2026 |
| 2026 revenue guidance | $9.680 billion to $9.960 billion | Zoetis Q1 2026 results release | July 9, 2026 |
| Fiscal 2025 revenue | $9.467 billion | Macrotrends and Zoetis 2025 annual report | July 9, 2026 |
| Fiscal 2025 net income | $2.673 billion | Zoetis 2025 annual report | July 9, 2026 |
| Fiscal 2025 free cash flow | $2.283 billion | Macrotrends | July 9, 2026 |
| Cash and equivalents | $2.312 billion at December 31, 2025 | Zoetis 2025 annual report and CompaniesMarketCap | July 9, 2026 |
| Total debt and net debt | $9.238 billion total debt and about $7.298 billion net debt on latest balance-sheet feeds | StockAnalysis and CompaniesMarketCap debt data | July 9, 2026 |
| Shares outstanding | 419.23 million | StockAnalysis statistics | July 9, 2026 |
| Market capitalization | $31.56 billion to $31.84 billion range across current feeds | StockAnalysis market cap and market quote feeds | July 9, 2026 |
| Technical levels | RSI 43.5 to 50.62, support near $71.86, resistance near $75.57 to $77.73 | Investing.com and AltIndex technical pages | July 9, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell ZTS. Forecast scenarios are based on available public data, source checks, and assumptions as of the stated cutoff date. They can be wrong if fundamentals, market prices, interest rates, litigation, competition, or investor sentiment change.
